These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11026025)

  • 1. [erbB2 as a prognostic factor of breast cancers].
    Nishimura R; Nagao K; Miyayama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():407-12. PubMed ID: 11026025
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation between c-erbB2 expression, lymphovascular invasion and other biological and clinical prognostic factors and preoperative tumor markers in patients with early-stage and locally advanced breast cancer.
    Aksu G; Duman C; Gurbuz Y; Ercin C; Canturk Z; Utkan Z; Dulger M
    J BUON; 2011; 16(1):52-7. PubMed ID: 21674850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
    Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
    Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Minimal breast cancer: some prognostic signs].
    Ermachenkova AM
    Vopr Onkol; 2013; 59(3):299-301. PubMed ID: 23909029
    [No Abstract]   [Full Text] [Related]  

  • 5. A study of breast cancer in young women: prognosis and prognostic factors.
    Saito E
    Nihon Geka Hokan; 1996 Nov; 65(4):133-44. PubMed ID: 9528272
    [No Abstract]   [Full Text] [Related]  

  • 6. [Epidermal growth factor receptor as a prognostic factor of breast cancers].
    Tsutsui S
    Nihon Rinsho; 2000 Apr; 58 Suppl():442-7. PubMed ID: 11026031
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)].
    Harbeck N
    MMW Fortschr Med; 2003 Jan; 145(3-4):8, 10. PubMed ID: 12619225
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular subtyping of early-stage breast cancer: implications for radiation therapy.
    Haffty BG; Goyal S
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1293-5. PubMed ID: 20637976
    [No Abstract]   [Full Text] [Related]  

  • 10. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
    Erdogan S; Ergin M; Tuncer I
    Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-erbB2 oncoprotein: prognostic marker in breast cancer.
    Roşian A; Lazăr E; Dema A
    Rom J Morphol Embryol; 2005; 46(2):99-104. PubMed ID: 16286993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A
    J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current aspects in histopathological assessment of breast cancer].
    Sastre X
    Bull Cancer; 1997 Jan; 84(1):65-8. PubMed ID: 9180862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.